Welcome to our dedicated page for Axos Financial SEC filings (Ticker: AX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Axos Financial, Inc. (NYSE: AX), the holding company for Axos Bank, Axos Clearing LLC, and Axos Invest, Inc. Through these filings, investors can review the company’s detailed financial statements, risk disclosures, governance information, and documentation of material events affecting the business.
Axos Financial’s SEC reporting includes annual reports on Form 10-K and quarterly reports on Form 10-Q, which present consolidated financial results for its Banking Business Segment and Securities Business Segment. These reports typically cover net interest income, non-interest income, provisions for credit losses, non-interest expense, segment performance, capital ratios, and metrics such as book value and tangible book value per common share. They also describe Axos Bank’s nationwide consumer and business banking activities and the securities clearing and digital advisory services provided by Axos Clearing and Axos Invest.
Current reports on Form 8-K document significant events such as earnings releases, material definitive agreements, capital markets transactions, and acquisitions. Recent 8-K filings describe Axos Financial’s issuance of 7.00% Fixed-to-Floating Rate Subordinated Notes due 2035, the agreement and subsequent closing of the acquisition of Verdant Commercial Capital, LLC, the purchase of a commercial office complex in San Diego, California that Axos Bank intends to occupy as its headquarters at a future date, and matters submitted to a vote of stockholders at the annual meeting. Other 8-Ks address changes involving directors or certain officers and the use of investor presentations.
The company’s proxy statement on Form DEF 14A provides information on board composition, director elections, executive compensation, equity incentive plans, and shareholder voting procedures. It also outlines the agenda for the annual meeting of stockholders and the board’s recommendations on each proposal, including advisory votes on executive compensation and ratification of the independent registered public accounting firm.
On Stock Titan, these filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents. Users can quickly identify major changes in Axos Financial’s financial condition, capital structure, governance, and strategic transactions, and then drill into the full text of 10-K, 10-Q, 8-K, and DEF 14A filings as needed. Insider transaction reports on Form 4 and other ownership-related filings, when available, can also be reviewed to understand trading activity by directors and officers.
Axos Financial director James John Court reported a sale of company stock. On February 6, 2026, he sold 11,163 shares of Axos Financial common stock at a weighted average price of $101.01 per share, through multiple trades between $100.77 and $101.42.
After this transaction, Court directly held 32,169 shares of Axos Financial common stock. The filing also notes an additional 1,200 shares held indirectly through his spouse’s IRA account.
Axos Financial insider files notice to sell common stock under Rule 144. The person for whose account the securities will be sold plans to sell 4,846 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 490,441.85, on or about 02/06/2026 on the NYSE.
The shares to be sold were acquired as restricted stock from the issuer in three transactions on 09/23/2024, 09/15/2025, and 09/23/2025, totaling 4,846 shares. The filing notes 56,678,249 shares of common stock outstanding.
Axos Financial, Inc. President and CEO Gregory Garrabrants, who is also a director, reported several transactions in Axos common stock. On February 4, 2026, he sold 43,294 shares of common stock at a weighted average price of $99.099 per share, leaving 1,418,751 shares owned directly after that sale.
On February 5, 2026, he made two charitable gifts: 1,513 shares at $98.97 per share, valued at $149,742, and 1,009 shares at $98.97 per share, valued at $99,861. After the reported transactions, he directly held 1,416,229 shares of Axos common stock, plus 2,890 shares held indirectly through a 401(k) Plan and 170,680 shares held indirectly by a trust.
An insider related to AX common stock has filed a Rule 144 notice to sell 11,163 shares. The proposed sale is through Morgan Stanley Smith Barney LLC on or around 02/06/2026 on the NYSE, with an aggregate market value of $1,127,592.49.
The filing notes that 56,678,249 AX common shares were outstanding. The shares to be sold were acquired as restricted stock from the issuer on several dates in 2023–2025, including grants on 08/15/2023, 08/31/2023, 08/31/2024, and 11/14/2025.
An AX shareholder filed a notice to sell 3,260 common shares under Rule 144, with an aggregate market value of $326,000, through Morgan Stanley Smith Barney on or around February 6, 2026 on the NYSE.
The issuer lists 56,678,249 common shares outstanding for this class. The shares to be sold were acquired as restricted stock directly from the issuer on several dates in September 2024 and September 2025, with payment described as not applicable.
AX has a planned sale of restricted common stock under Rule 144. A holder intends to sell 43,294 common shares through Morgan Stanley Smith Barney LLC on or about 02/04/2026 on the NYSE, with an aggregate market value of $4,290,379.20.
These shares were acquired as restricted stock from the issuer on 06/30/2025, in the same amount of 43,294 shares. The filing notes that 56,678,249 common shares were outstanding when this notice was prepared.
AX has a planned sale of restricted shares under Rule 144. A holder filed to sell 32,719 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 3,224,850.08 and total shares outstanding of 56,678,249. The shares were acquired on 08/01/2023 through restricted stock vesting under a registered plan, with the approximate sale date listed as 02/03/2026.
Axos Financial, Inc. filed a Form 8-K to furnish a Regulation FD disclosure about an investor presentation. The company plans to use the materials in investor meetings beginning on or around February 2, 2026 and over the next few months. The presentation is provided as Exhibits 99.1 and 99.2 and is expressly furnished, not deemed filed under the Exchange Act or incorporated by reference into other securities filings unless specifically referenced.
The company with ticker AX has a shareholder planning to sell 18,192 shares of common stock under Rule 144. The planned sale, through Morgan Stanley Smith Barney LLC on the NYSE around 01/30/2026, has an aggregate market value of $1,764,072.78. The filing notes 56,678,249 shares outstanding and shows these shares were acquired as restricted stock from the issuer on 08/28/2021.
Axos Financial, Inc. reported strong quarterly growth for the three months ended December 31, 2025. Net income rose to $128.4 million from $104.7 million a year earlier, and diluted earnings per share increased to $2.22 from $1.80. Net interest income reached $331.7 million, up from $280.1 million, driven by higher loan balances.
Total assets increased to $28.2 billion from $24.8 billion as loans held for investment grew to $24.8 billion. Deposits rose to $23.2 billion, while stockholders’ equity expanded to $2.93 billion. The allowance for credit losses on loans increased to $327.0 million, reflecting portfolio growth and updated economic assumptions.
Axos completed the all-cash acquisition of Verdant Commercial Capital, LLC on September 30, 2025. The transaction brought in about $1.2 billion of loans and leases and total consideration of approximately $566.9 million, including settlement of Verdant debt and up to $50.0 million of performance-based contingent consideration. Verdant contributed $30.1 million of net revenue for the period.